益佰制药
(600594)
| 流通市值：28.35亿 | | | 总市值：28.35亿 |
| 流通股本：7.92亿 | | | 总股本：7.92亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 501,480,776.32 | 2,174,031,578.87 | 1,713,840,317.37 | 1,168,191,423.5 |
| 营业收入 | 501,480,776.32 | 2,174,031,578.87 | 1,713,840,317.37 | 1,168,191,423.5 |
| 二、营业总成本 | 512,206,331.73 | 2,434,804,131.13 | 1,842,847,294.11 | 1,265,385,630.58 |
| 营业成本 | 199,750,438.51 | 829,439,868.55 | 647,908,117.57 | 438,677,697.07 |
| 税金及附加 | 9,495,737.22 | 31,964,513.94 | 25,717,399.32 | 16,528,932.01 |
| 销售费用 | 209,303,987.7 | 1,096,787,271.38 | 823,502,438.57 | 581,646,259.15 |
| 管理费用 | 65,498,418.93 | 356,353,860.05 | 250,408,193.03 | 163,906,482.89 |
| 研发费用 | 20,616,783.17 | 100,501,932.5 | 79,177,945.47 | 52,148,931.55 |
| 财务费用 | 7,540,966.2 | 19,756,684.71 | 16,133,200.15 | 12,477,327.91 |
| 其中:利息费用 | 7,955,759.42 | 26,394,706.81 | 21,271,856.68 | 16,042,041.77 |
| 其中:利息收入 | 931,862.08 | 7,034,545.99 | 5,715,702.93 | 4,186,558.75 |
| 加:投资收益 | -125,985.5 | 338,405.75 | 146,759.24 | 150,246.77 |
| 资产处置收益 | 9,779.53 | 779,233.88 | 646,711.69 | 89,603.73 |
| 资产减值损失(新) | -6,607,395.18 | -78,911,500.4 | -48,293,610.56 | -18,277,192.4 |
| 信用减值损失(新) | -831,344.18 | 4,696,452.48 | -2,615,865.64 | -1,624,225.36 |
| 其他收益 | 7,802,422.76 | 21,616,488.72 | 15,651,499.98 | 10,423,555.42 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -10,478,077.98 | -312,253,471.83 | -163,471,482.03 | -106,432,218.92 |
| 加:营业外收入 | 891,278.61 | 1,842,206.48 | 649,810.26 | 545,438.33 |
| 减:营业外支出 | 412,743.67 | 22,109,446.94 | 10,944,727.49 | 8,137,762.82 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -9,999,543.04 | -332,520,712.29 | -173,766,399.26 | -114,024,543.41 |
| 减:所得税费用 | 1,428,294.49 | 2,153,275.09 | 475,420.6 | -3,050,559.84 |
| 六、净利润 | -11,427,837.53 | -334,673,987.38 | -174,241,819.86 | -110,973,983.57 |
| 持续经营净利润 | -11,427,837.53 | -334,673,987.38 | -174,241,819.86 | -110,973,983.57 |
| 归属于母公司股东的净利润 | -9,385,719.46 | -317,215,358.07 | -169,151,279.27 | -106,493,434.06 |
| 少数股东损益 | -2,042,118.07 | -17,458,629.31 | -5,090,540.59 | -4,480,549.51 |
| (一)基本每股收益 | -0.01 | -0.4 | -0.21 | -0.13 |
| (二)稀释每股收益 | -0.01 | -0.4 | -0.21 | -0.13 |
| 八、其他综合收益 | - | -198,981.06 | 27,008.83 | 39,540.83 |
| 归属于母公司股东的其他综合收益 | - | -198,981.06 | 27,008.83 | 39,540.83 |
| 九、综合收益总额 | -11,427,837.53 | -334,872,968.44 | -174,214,811.03 | -110,934,442.74 |
| 归属于母公司股东的综合收益总额 | -9,385,719.46 | -317,414,339.13 | -169,124,270.44 | -106,453,893.23 |
| 归属于少数股东的综合收益总额 | -2,042,118.07 | -17,458,629.31 | -5,090,540.59 | -4,480,549.51 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-26 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |